NIBSC Scientist - Gene Therapy

South Mimms, Potters Bar
£38301 per annum plus benefits
Oct 05, 2016
Oct 23, 2016
Result Type
Position Type
Full Time

POSITION:  Scientist
DIVISION:  Advanced Therapies
LOCATION: NIBSC, South Mimms, Potters Bar, Hertfordshire EN6 3QG
TYPE OF CONTRACT:  Full time – Permanent

The Medicines and Healthcare products Regulatory Agency enhance and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research. The agency is made up of circa 1300 staff working across two main centres and peripatetically across the UK and abroad.

A centre of the Medicines and Healthcare products Regulatory Agency, The National Institute for Biological Standards and Control (NIBSC) is a global leader in the characterisation, standardisation and control of biological medicines. NIBSC plays a major role in assuring the quality of biological medicines worldwide through the provision of biological reference materials, by testing products and carrying out research. Our expert scientists also provide advice on a routine basis and in response to emergencies. 

Purpose of the role:

The Division of Advanced Therapies is tasked with the provision of standards, controls and research to underpin the clinical application of advanced therapies (gene therapy, stem cell therapy and tissue engineering). The division produces qualified cell banks for use in vaccine manufacture and 12 genomic reference materials for in vitro diagnostic use, from the WHO International Standards to the CE-marked reference materials.  

Current research and development in gene therapy has highlighted the potential of a number of new products moving through clinical trials into licensed medicines and signifies the increasing need for the standardisation of gene therapy products. Gene therapy section collaborates closely with other laboratories within NIBSC, as well as external laboratories throughout the UK and internationally.  

If successful, the post holder will help build up capability and resilience in future gene therapy standardisation area.